FY2025 EPS Estimates for AngioDynamics Boosted by Analyst

AngioDynamics, Inc. (NASDAQ:ANGO) – Research analysts at HC Wainwright upped their FY2025 EPS estimates for shares of AngioDynamics in a research report issued on Monday, April 7th. HC Wainwright analyst Y. Chen now expects that the medical instruments supplier will post earnings per share of ($0.21) for the year, up from their previous estimate of ($0.38). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for AngioDynamics’ Q4 2025 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.28) EPS.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.16. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm had revenue of $72.00 million during the quarter, compared to the consensus estimate of $70.30 million. AngioDynamics’s quarterly revenue was down 4.3% compared to the same quarter last year.

AngioDynamics Trading Up 6.1 %

ANGO stock opened at $9.55 on Thursday. The company’s 50 day moving average is $9.87 and its 200 day moving average is $8.93. AngioDynamics has a 1-year low of $5.47 and a 1-year high of $13.50. The stock has a market cap of $386.45 million, a price-to-earnings ratio of -1.70 and a beta of 0.52.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AngioDynamics

Hedge funds have recently made changes to their positions in the business. SBI Securities Co. Ltd. purchased a new position in shares of AngioDynamics in the 4th quarter worth approximately $28,000. R Squared Ltd bought a new stake in AngioDynamics during the 4th quarter valued at $49,000. US Bancorp DE boosted its position in shares of AngioDynamics by 1,938.0% in the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier’s stock worth $61,000 after purchasing an additional 6,376 shares in the last quarter. Quinn Opportunity Partners LLC purchased a new stake in shares of AngioDynamics during the fourth quarter valued at $92,000. Finally, ProShare Advisors LLC purchased a new stake in AngioDynamics in the fourth quarter valued at $100,000. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.